mCRPC VL

Clinically Relevant Biomarkers in Castration-Resistant Prostate Cancer - Noel Clarke

Details
Alicia Morgans is joined by Noel Clarke to discuss his work in clinically relevant biomarkers in castration-resistant prostate cancer (CRPC). Professor Clarke emphasizes the importance of using the available data that you have, keeping the patient at the very center of your thought processes, and regarding the patient as a whole rather than someone with prostate cancer. He highlights factors such...

Combination of Niraparib and Abiraterone Acetate Plus Prednisone Radiographic PFS as a First-Line Therapy in Patients with HRR Gene-Mutated mCRPC, MAGNITUDE - Cora Sternberg

Details
Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr. Sternbe...

Heterogeneity in Multifocal Prostate Cancer - Simpa Salami

Details
In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis. Simpa Salami is a Prostate Cancer Foundation (PCF) Young Investigator Award recipient. Highlighting key takeaways from two research studies, Dr. Salami also shares how the PCF funding has supported this r...

A Urine-Based Multiplexed Assay for the Early Detection of Aggressive Prostate Cancer – Simpa Salami

Details
In this conversation with Charles Ryan, Simpa Salami highlights a new urine-based test for detecting aggressive prostate cancer, which promises improvement upon current biomarker tests. It's been estimated that prostate cancer often occurs in multiple areas of the prostate in about 60% to 80% of patients. Prostate biopsy is the strategy for detecting aggressive prostate cancer based upon elevated...

Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce

Details
In this conversation, Alicia Morgans and Alan Bryce highlighted the TRITON3 study. TRITON3 is a Phase 3, multicenter, open-label, randomized trial of Rubraca in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 405 patients with a mutation in BRCA or ATM who were randomized to Rubraca or the control group, which consisted of the physician’...

Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris

Details
In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...

Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade

Details
Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, cancer adapts to this new environment and PSA levels start to rise. The concept of BAT is for men whose prostate cancer has become resistant to standard ho...

Comprehensively Mapping Epigenetic Alterations Promoting Lineage Plasticity to Develop Blood-based Biomarkers to Predict Treatment Outcomes in Prostate Cancer - Martin Sjöström

Details
Martin Sjöström joins Alicia Morgans in a conversation on the 2021 Michael and Patricia Berns-PCF Young Investigator Award research studying epigenetic modifications that drive lineage plasticity and treatment resistance in prostate cancer. This research aims to develop a new liquid biopsy biomarker platform for men with prostate cancer. Sjöström refers to the ability to take a blood sample and pr...

Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis

Details
Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. The COMBAT study is a multi-center, single-arm, open label Phase 2 study in asymptomatic patients with mCRPC who had soft tissue metastases amenable to biopsy, and who progressed on at least one prior novel AR-targeted therapy (and up...

Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
email news signup